<DOC>
	<DOCNO>NCT00003129</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness chemotherapy treat patient early-stage bladder cancer respond BCG therapy .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Early-Stage Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine recurrence rate disease free survival patient recurrent refractory papillary transitional cell carcinoma bladder without carcinoma situ bladder treat intravesical AD 32 . - Evaluate safety administer drug patient . - Determine effectiveness drug , term recurrence rate disease free survival , patient . OUTLINE : Patients stratify accord cellular diagnosis ( papillary transitional cell carcinoma ( Ta/T1 ) carcinoma situ ( Tis ) v Tis without Ta/T1 ) . Patients receive intravesical AD 32 week 6 week . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 75 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Valrubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent superficial bladder cancer define papillary transitional cell carcinoma ( stage Ta/T1 ) and/or carcinoma situ ( stage Tis ) urinary bladder No evidence invasion underlie muscle ( stage T2 ) baseline Must meet 1 follow criterion : Failure least 2 prior course intravesical therapy , 1 must course BCG Recurrent persistent disease within 6 month fail 6week course BCG follow maintenance therapy Inability ineligibility complete 1 course intravesical therapy BCG , failure 2 prior course intravesical therapy alternative agent Diagnosis must make 24 month completion prior treatment intravesical immunotherapy chemotherapy If carcinoma situ current previous diagnosis , biopsy must obtain least 4 site ( bladder mapping ) If prostatic urothelial biopsy disclose carcinoma situ , transurethral prostatic resection must carry prior study Papillary disease must undergo complete transurethral resection ( TURBT ) within 28 day study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT SGPT less 3 time ULN Renal : Creatinine great 2.5 mg/dL Other : Normal upper tract ( ureter renal pelvic ) evaluation within 6 month No known sensitivity anthracyclines Cremophor EL HIV negative No known AIDS HIV1 associate complex No significant concurrent illness No prior malignancy within past 3 year except superficial bladder cancer , adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent biological response modifier therapy Chemotherapy : See Disease Characteristics Prior oral bropirimine bladder cancer allow No prior AD 32 bladder cancer No intravenously administer systemic chemotherapy bladder cancer No concurrent chemotherapy malignancy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>